Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)


The study is designed to evaluate the efficacy and safety of SHP465 in the treatment of ADHD in children and adolescents (aged 6-17 years). The primary objective of this study is to evaluate the efficacy of SHP465 administered as a daily morning dose compared to placebo in the treatment of children and adolescents (6-17 years of age inclusive) diagnosed with ADHD.

Study Start Date

June 2015

Estimated Completion Date

February 2016


  • Drug: SHP465
  • Drug: Placebo


  • Pediatrics: Child/Adolescent Psych
  • Psychiatry: Child/Adolescent Psych,Neuro/Psych Pharmacol,Neuropsych Sciences
  • Neurology: Neuro/Psych pharmacology,Neuropsych Sciences
  • Pharmacy: Neuro/Psych pharmacology

MeSH Terms

  • Attention Deficit Disorder with Hyperactivity
  • Dyskinesias
  • Hyperkinesis
  • Mental Disorders

Study ID

Shire -- SHP465-305



Trial ID


Study Type


Trial Phase

Phase 3

Enrollment Quota




Inclusion Criteria

    1. Subject must be 6-17 years of age, inclusive, at the time of consent. 2. Subject's parent or legally authorized representative (LAR) must provide signature of informed consent, and there must be documentation of assent (if applicable) by the subject indicating that the subject is aware of the investigational nature of the study and the required procedures and restrictions in accordance with the ICH GCP Guideline E6 (1996) and applicable regulations before completing any study-related procedures. 3. Subject and parent/LAR are willing and able to comply with all of the testing and requirements defined in the protocol, including oversight of morning dosing. Specifically, the parent/LAR must be available at approximately 7:00AM (±2 hours) to dispense the dose of investigational product for the study duration. 4. Subject, who is a female and of child-bearing potential, must not have a positive serum beta human chorionic gonadotropin pregnancy test at the Screening Visit (Visit 1) and must have a negative urine pregnancy test at the Baseline Visit (Visit 2) and agree to comply with any applicable contraceptive requirements of the protocol. 5. Subject must have a satisfactory medical assessment with no clinically significant or relevant abnormalities. 6. Subject meets DSM-IV-TR criteria for a primary diagnosis of ADHD based on a detailed psychiatric evaluation. 7. Subject has an ADHD-RS-IV Total Score >28 at the Baseline Visit (Visit 2). 8. Subject is functioning at an age-appropriate level intellectually, as determined by the study Investigator. 9. Subject is currently not on ADHD therapy, or is not completely satisfied with any aspect of their current ADHD therapy. 10. Subject is able to swallow a capsule whole.

Exclusion Criteria

    1. Subject has a current, controlled (with medications prohibited in this study) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any significant comorbid Axis II disorder or significant Axis I disorder (such as post-traumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, depressive or anxiety disorder) or other symptomatic manifestations that, in the opinion of the examining clinician, will contraindicate treatment with SHP465 or confound efficacy or safety assessments. Comorbid psychiatric diagnoses will be established with the Screening Visit (Visit 1) interview of the K-SADS-PL and additional modules if warranted by the results of the initial interview. Subjects may continue participation in a behavioral modification program during the study as long as they have been participating in the program for at least 1 month at the time of the Baseline Visit (Visit 2). 2. Subject meets DSM-IV-TR diagnosis of conduct disorder. Oppositional defiant disorder is not exclusionary. 3. Subject is considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the Investigator. 4. Subject is underweight based on Centers for Disease Control and Prevention body mass index (BMI)-for-age sex-specific values at the Screening Visit (Visit 1). Underweight is defined as a BMI <3rd percentile 5. Subject is significantly overweight based on Centers for Disease Control and Prevention BMI-for-age sex specific values at the Screening Visit (Visit 1). Significantly overweight is defined as a BMI >97th percentile for this study 6. Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition that might confound the results of safety assessments conducted in the study or that might increase risk to the subject. Similarly, the subject will be excluded if he or she has any additional condition(s) that, in the Investigator's opinion, would prohibit the subject from completing the study or would not be in the best interest of the subject. The additional conditions would include any significant illness or unstable medical condition that could lead to difficulty complying with the protocol. Mild, stable asthma is not exclusionary. 7. Subject has a history of seizure (other than infantile febrile seizures), a chronic or current tic disorder, or a current diagnosis of Tourette's Disorder. Subject has a history of tics that are judged by the Investigator to be exclusionary. 8. Subject's blood pressure measurements exceed the 90th percentile for age, sex, and height (based on the Blood Pressure Levels by Age and Height Percentile [for boys and girls]) at the Screening Visit (Visit 1) and the Baseline Visit (Visit 2) 9. Subject has a known history of hypertension 10. Subject has a known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place him/her at increased vulnerability to the sympathomimetic effects of a stimulant medication. 11. Subject has a known family history of sudden cardiac death or ventricular arrhythmia. 12. Subject has any clinically significant ECG or clinically significant laboratory abnormality at the Screening Visit (Visit 1). 13. Subject has current abnormal thyroid function, defined as abnormal thyroid stimulating hormone and thyroxine at the Screening Visit (Visit 1). Treatment with a stable dose of thyroid medication for at least 3 months is permitted. 14. Subject has a documented allergy, hypersensitivity, or intolerance to amphetamine or to any excipients in the investigational product. 15. Subject has failed to respond, based on Investigator judgment, to an adequate course(s) (dose and duration) of amphetamine therapy 16. Subject has a history of suspected substance abuse or dependence disorder (excluding nicotine) in accordance with DSM-IV-TR criteria. Subjects with a lifetime history of amphetamine, cocaine, or other stimulant abuse and/or dependence will be excluded. 17. Subject has a positive urine drug result at the Screening Visit (Visit 1) (with the exception of subject's current stimulant therapy, if any) or the Baseline Visit (Visit 2), if repeated unless the Investigator can verify that the positive result at the Screening Visit (Visit 1) is attributed to medication that has been prescribed to the subject and will be discontinued prior to the Baseline Visit (Visit 2). A positive result at the Screening Visit (Visit 1) attributed to a prescribed medication requires a re-test and a negative result at the Baseline Visit (Visit 2) to confirm subject eligibility. 18. Subject has taken another investigational product or has taken part in a clinical study within 30 days prior to the Screening Visit (Visit 1). 19. Subject has previously completed, discontinued, or was withdrawn from this study. 20. Subject is taking any medication that is excluded or has not been appropriately washed out according to the protocol requirements. 21. Subject is required to take or anticipates the need to take medications that have central nervous system effects or affect performance, such as sedating antihistamines and decongestant sympathomimetics, or are monoamine oxidase inhibitors. Stable use of bronchodilator inhalers is not exclusionary. 22. Subject is female and is pregnant or lactating




6 Years to 17 Years

Accepts Healthy Volunteers


Study Locations and Contact Information (36)

Study Location Distance Name Phone Email
Omega Medical Research - Warwick, Rhode Island 49.1 miles None None None
Rochester Center For Behavioral Medicine - Rochester Hills, Michigan 613.5 miles None None None
Midwest Clinical Research Center - Dayton, Ohio 708.9 miles None None None
Coastal Carolina Research Center - Mt. Pleasant, South Carolina 815.9 miles None None None
Rainbow Research - Barnwell, South Carolina 843.9 miles None None None
Capstone Clinical Research - Libertyville, Illinois 861.5 miles None None None
Baber Research Group Inc - Naperville, Illinois 876.6 miles None None None
Northwest Behavioral Research Center - Marietta, Georgia 933.9 miles None None None
Clinical Neuroscience Solutions Inc - Jacksonville, Florida 1,021.9 miles None None None
Psychiatric Care and Research Center - O'fallon, Missouri 1,045.1 miles None None None
Midwest Research Group - St. Charles, Missouri 1,055.2 miles None None None
Sarkis Clinical Trials - Gainesville, Florida 1,083.3 miles None None None
Medical Research Group of Central Florida - Orange City, Florida 1,090.5 miles None None None
Harmonex Neuroscience Research - Dothan, Alabama 1,102.1 miles None None None
Clinical Neuroscience Solutions Inc - Orlando, Florida 1,117.3 miles None None None
Clinical Neuroscience Solution Inc - Memphis, Tennessee 1,128.4 miles None None None
Janus Center For Psychiatric Research - West Palm Beach, Florida 1,194.5 miles None None None
Florida Clinical Research Center Llc - Bradenton, Florida 1,219.8 miles None None None
Psychiatric Associates - Overland Park, Kansas 1,255.4 miles None None None
Miami Research Associates Llc - South Miami, Florida 1,267.3 miles None None None
Louisiana Research Associates Inc - New Orleans, Louisiana 1,359.4 miles None None None
Tulsa Clinical Research Llc - Tulsa, Oklahoma 1,394.9 miles None None None
Research Across America - Plano, Texas 1,541.8 miles None None None
Futuresearch Trials of Dallas Lp - Dallas, Texas 1,545.0 miles None None None
Red Oak Psychiatry Associates Pa - Houston, Texas 1,598.9 miles None None None
Bayou City Research - Houston, Texas 1,607.2 miles None None None
Houston Clinical Trials Llc - Houston, Texas 1,609.5 miles None None None
McB Clinical Research Centers - Colorado Springs, Colorado 1,776.6 miles None None None
Westex Clinical Investigations - Lubbock, Texas 1,777.9 miles None None None
Center For Psychiatry and Behavioral Medicine - Las Vegas, Nevada 2,380.5 miles None None None
Eastside Therapeutic Resource - Kirkland, Washington 2,482.2 miles None None None
Elite Clinical Trials Inc - Wildomar, California 2,559.4 miles None None None
Oregon Center For Clinical Investigations Inc - Salem, Oregon 2,561.0 miles None None None
Encompass Clinical Research - Spring Valley, California 2,572.2 miles None None None
Pcsd Feighner Research - San Diego, California 2,580.0 miles None None None
Nrc Research Institute - Orange, California 2,585.0 miles None None None provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.